NexoBrid ® is a topically administered biological orphan drug that enzymatically removes eschar while preserving viable tissue in patients with deep partial- and full-thickness thermal burns. It is ...

MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced ...

MediWound (MDWD) announced the publication of its Phase III Children Innovative Debridement Study in Burns, the peer-reviewed Journal of the ...

Valeo Financial Advisors LLC cut its stake in Vericel Co. (NASDAQ:VCEL – Free Report) by 19.7% during the 4th quarter, ...

Learn more about whether PTC Therapeutics, Inc. or Vericel Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Vericel Corporation or Veracyte, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

MediWound currently markets NexoBrid which is approved for eschar removal in adult and pediatric patients with deep partial thickness and/or full thickness thermal burns in several geographies ...

We trained a convolutional neural network (CNN) to classify four burn severities: SPF (superficial), SPT (superficial partial thickness), DPT (deep partial thickness), and FT (full thickness).